PACLITAXEL

Growth

paclitaxel

NDAINTRAVENOUSPOWDER
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of…

Pharmacologic Class:

Microtubule Inhibitor

Clinical Trials (5)

NCT07433673Phase 2Recruiting

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Started Aug 2026
20 enrolled
Colon and Rectal Cancer
NCT07362186Phase 3Not Yet Recruiting

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Started Apr 2026
NCT07445295Phase 3Not Yet Recruiting

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started Mar 2026
NCT07290140N/ANot Yet Recruiting

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Started Mar 2026
NCT07432594Phase 2Not Yet Recruiting

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Started Mar 2026